Ocumension Therapeutics has reiterated that, following the electronic dissemination policy announced on 27 February 2025, all future corporate communications—including annual and interim reports, meeting notices, circulars, listing documents and proxy forms—will be provided solely via the company’s website (www.ocumension.com) and the HKEXnews portal (www.hkexnews.hk).

Shareholders have until 29 May 2026 to submit a valid email address—either by scanning the personalised QR code on the enclosed reply form or by returning the completed form to Computershare Hong Kong Investor Services Limited, Ocumension’s Hong Kong share registrar. Failure to respond by the deadline will be taken as deemed consent to receive all future documents electronically via the designated websites.

Key operational points:

• Email registration: If multiple addresses are submitted, only the most recently provided address will be recorded. • Absence of a functional email: Shareholders risk missing publication notices and will need to check the company and HKEXnews websites proactively; actionable corporate communications will continue to be sent in print. • Printed copies: Investors preferring hard-copy documents must request them via the reply form or email (ocumension.ecom@computershare.com.hk). This preference remains valid for one year from receipt of the instruction. • Enquiries: The Hong Kong share registrar can be reached at (852) 2862 8688, Monday to Friday, 9:00 a.m.-6:00 p.m. (Hong Kong time), excluding public holidays.

The reminder underscores Ocumension’s transition to a fully electronic communication framework, aligning with sustainability initiatives and regulatory guidelines while maintaining optionality for shareholders who opt for printed materials.